A Perspective of the Amide Group Containing FDA Approved Anticancer Drugs from 2021-2022 (A Review)

被引:9
作者
Asif, Mohd [1 ]
Srivastava, Rohan [1 ]
Fatima, Alisha [1 ]
Shakeel, Mazhar [1 ]
Hassan, Firoz [1 ]
Nasibullah, Malik [1 ]
机构
[1] Integral Univ, Lucknow 226026, India
关键词
amide group; FDA; drugs; side effects; medical treatment; TRIAL EVALUATING SOTORASIB; LUNG-CANCER NSCLC; ROPEGINTERFERON ALPHA-2B; PROSTATE-CANCER; OPEN-LABEL; MULTICENTER; AMIVANTAMAB; INHIBITOR; EFFICACY; OUTCOMES;
D O I
10.1134/S1068162023060018
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In this review, we describe a collection and assessment of 16 anticancer drugs approved by the U.S. FDA between 2021 to June 2022, which include small and big amide group containing compounds. All the 16 drugs have been approved for the treatment of different types of cancer. The amide group containing approved drugs listed and described in the following order: year of permission, donor, goal, pharmacological category, and significant drug-metabolizing enzyme, technique of administration or elimination mechanism, and pharmacological and toxicological susceptibility. Moreover, the skeleton of the approved drugs was being also analyzed through stereochemistry. The aromatic/aliphatic character of the molecules has been made important in pharmacophores and effective elements such as sulphur, nitrogen, halogens, and active functional groups. The diversity of effective drugs for cancer treatment is needed for the present.
引用
收藏
页码:1165 / 1176
页数:12
相关论文
共 95 条
[1]   Glycyrrhizic Acid Scavenges Reactive Carbonyl Species and Attenuates Glycation-Induced Multiple Protein Modification: An In Vitro and In Silico Study [J].
Alvi, Sahir Sultan ;
Nabi, Rabia ;
Khan, Mohd Shahnawaz ;
Akhter, Firoz ;
Ahmad, Saheem ;
Khan, M. Salman .
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2021, 2021
[2]   Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castrationresistant prostate cancer in the VISION trial [J].
Armstrong, A. J. ;
Sartor, O. ;
Saad, F. ;
Czernin, J. ;
Shore, N. D. ;
Kendi, A. T. ;
Beer, T. M. ;
Vaishampayan, N. ;
El-Haddad, G. ;
Wu, J. ;
Mirante, O. ;
Morris, M. J. .
ANNALS OF ONCOLOGY, 2022, 33 (07) :S1169-S1170
[3]  
ascopost, ASCO Treatment Guidance for Metastatic Castration-Resistant Prostate Cancer Updated to Include LuPSMA-The ASCO Post
[4]   Novel Functionalized Spiro [Indoline-3,5′-pyrroline]-2,2′dione Derivatives: Synthesis, Characterization, Drug-Likeness, ADME, and Anticancer Potential [J].
Asif, Mohd ;
Alvi, Sahir Sultan ;
Azaz, Tazeen ;
Khan, Abdul Rahman ;
Tiwari, Bhoopendra ;
Hafeez, Bilal Bin ;
Nasibullah, Malik .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (08)
[5]   Lewis base-catalyzed synthesis of highly functionalized spirooxindole-pyranopyrazoles and their in vitro anticancer studies [J].
Asif, Mohd ;
Aqil, Farrukh ;
Alasmary, Fatmah Ali ;
Almalki, Amani Salem ;
Khan, Abdul Rahman ;
Nasibullah, Malik .
MEDICINAL CHEMISTRY RESEARCH, 2023, 32 (05) :1001-1015
[6]   Propagative isatin in organic synthesis of spirooxindoles through catalysis [J].
Asif, Mohd ;
Azaz, Tazeen ;
Tiwari, Bhoopendra ;
Nasibullah, Malik .
TETRAHEDRON, 2023, 134
[7]   Synthesis of Functionalized 2′,5-Oxo-spiro[furan-2,3′-indoline]-3-carboxylate Derivatives as Antiproliferative Agents: ADMET Studies, and Molecular Docking against P2Y12 Inhibitors [J].
Asif, Mohd ;
Saquib, Mohammad ;
Rahman Khan, Abdul ;
Aqil, Farrukh ;
Salem Almalki, Amani ;
Ali Alasmary, Fatmah ;
Singh, Jaya ;
Nasibullah, Malik .
CHEMISTRYSELECT, 2023, 8 (11)
[8]  
Bahler Clinton D, 2017, J Endourol B Videourol, V31, DOI [10.1089/vid.2016.0068, 10.1089/vid.2016.0068]
[9]   Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial [J].
Barbui, Tiziano ;
Vannucchi, Alessandro Maria ;
De Stefano, Valerio ;
Masciulli, Arianna ;
Carobbio, Alessandra ;
Ferrari, Alberto ;
Ghirardi, Arianna ;
Rossi, Elena ;
Ciceri, Fabio ;
Bonifacio, Massimiliano ;
Iurlo, Alessandra ;
Palandri, Francesca ;
Benevolo, Giulia ;
Pane, Fabrizio ;
Ricco, Alessandra ;
Carli, Giuseppe ;
Caramella, Marianna ;
Rapezzi, Davide ;
Musolino, Caterina ;
Siragusa, Sergio ;
Rumi, Elisa ;
Patriarca, Andrea ;
Cascavilla, Nicola ;
Mora, Barbara ;
Cacciola, Emma ;
Mannarelli, Carmela ;
Loscocco, Giuseppe Gaetano ;
Guglielmelli, Paola ;
Betti, Silvia ;
Lunghi, Francesca ;
Scaffidi, Luigi ;
Bucelli, Cristina ;
Vianelli, Nicola ;
Bellini, Marta ;
Finazzi, Maria Chiara ;
Tognoni, Gianni ;
Rambaldi, Alessandro .
LANCET HAEMATOLOGY, 2021, 8 (03) :E175-E184
[10]   Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naive EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. [J].
Bauml, Joshua ;
Cho, Byoung Chul ;
Park, Keunchil ;
Lee, Ki Hyeong ;
Cho, Eun Kyung ;
Kim, Dong-Wan ;
Kim, Sang-We ;
Haura, Eric B. ;
Sabari, Joshua K. ;
Sanborn, Rachel E. ;
Nagasaka, Misako ;
Ou, Sai-Hong Ignatius ;
Minchom, Anna Rachel ;
Gomez, Jorge E. ;
Curtin, Joshua C. ;
Gao, Grace ;
Roshak, Amy ;
Thayu, Meena ;
Knoblauch, Roland Elmar ;
Spira, Alexander I. .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)